Form D · Biotechnology
M3dicine Holdings Inc.
San Francisco, CA · CIK 0001763406
Offering snapshot reported Jan 3, 2019 · SEC filing
- Reported sold
- $600K Offering amount: $3M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Dec 22, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 3, 2019 | Initial | $600,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-329594
Source: Form D, filed Jan 3, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nayyar Hussain | Director, Executive |
| Shabbir Hussain | Director |
| Shamile Hussain | Director, Executive |
| Munir Hussain | Director |
| Stephen Randall | Director, Executive |
| Pablo Rivas | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2229 Beach Street
San Francisco, CA, 94123
San Francisco, CA, 94123